Korro Bio has secured approvals in Australia to commence the Phase I/IIa trial of KRRO-110, aimed at treating AATD.

Rallybio has commenced an open-label Phase II trial of RLYB212 in pregnant women at higher risk for HPA-1a alloimmunisation ...

ImmunityBio has partnered with nCartes to automate and expedite the data fulfilment process for clinical trials.

Endeavor has dosed the first subject in the randomised Phase IIb WHISTLE-PF trial of ENV-101 (taladegib) for IPF.

Dubbed Nubeqa but known generically as darolutamide, the treatment comes in combination with androgen deprivation therapy ...

Puma Biotechnology has commenced the Phase II trial, ALISCA-Breast1, to evaluate oral alisertib, a selective inhibitor of ...

The company’s VP of digital excellence explains how the Japanese biotech engages with data and uses it to inform decision ...

Melt Pharmaceuticals has reported results from its Phase III trial of MELT-300 non-opioid sedation tablet for cataract ...

GigaGen, a subsidiary of Grifols, has commenced a Phase I trial, with the first patient receiving a dose of GIGA-2339 aimed ...

MSD has reported positive topline outcomes from the Phase III study of subcutaneous pembrolizumab in conjunction with ...

The consortium aims to attract global pharma and medical device companies for clinical trial research investment in Israel.

The FDA has released a draft of new guidance addressing common FAQs about the development of potential CGT treatments.